Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy

References

• Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13–18.
   PubMed Web of Science ®Google Scholar
• Flores NM, Villa KF, Black J, et al. The humanistic and economic burden of narcolepsy. J Clin Sleep Med. 2016;12(3):401–407. DOI:10.5664/jcsm.5594
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Abad VC. Narcolepsy. Chokroverty S, editor. Philadelphia: Saunders; 2009. p. 377–396.
   Google Scholar
• American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien IL: American Academy of Sleep Medicine; 2014.
   Google Scholar
• Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep. 2007;30:13–26.
   PubMed Web of Science ®Google Scholar
• Khatami R, Luca G, Baumann CR, et al. The European narcolepsy network (EU-NN database. J Sleep Res. 2016;25:356–364.
   PubMed Web of Science ®Google Scholar
• Silber MH, Krahn LE, Olson EJ, et al. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002 15;25:197–202. DOI:10.1093/sleep/25.2.197
   PubMed Web of Science ®Google Scholar
• Shin YK, Yoon IY, Han EK, et al. Prevalence of narcolepsy-cataplexy in Korean adolescents. Acta Neurol Scand. 2008;117:273–278.
   PubMed Web of Science ®Google Scholar
• Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother. 2019;20(10):1189–1199.
   PubMed Web of Science ®Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021 Sep 1;17(9):1895–1945. DOI:10.5664/jcsm.9326
   PubMed Web of Science ®Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–1893. DOI:10.5664/jcsm.9328
   PubMed Web of Science ®Google Scholar
• Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res. 2021;30(6):e13387. Epub 2021 Jun 25. PMID: 34173288 DOI:10.1111/jsr.13387
   PubMed Web of Science ®Google Scholar
• Billiard M, Dauvilliers Y, Dolenc-Groselj L, et al. Management of narcolepsy in adults. In: Gilhus N, Barnes M, and Brainin M, editors. European handbook of neurological management. Vol. 1. 2nd. Hoboken NJ: Wiley-Blackwell; 2011. p. 513–528. 978-1-405-18533-2.
   Google Scholar
• Worldometer US Population. Available at https://www.worldometers.info/world-population/us-population/[Last accessed 15 Dec 2022]
   Google Scholar
• Guilleminault C, Carskadon M, Dement WC. ON the treatment of rapid eye movement narcolepsy. Arch Neurol. 1974;30(1):90–93.
   PubMedGoogle Scholar
• Jazz Investor Presentation. Available at https://investor.jazzpharma.com/static-files/06208335-fa83-4259-89e9-9aff54a8ddc6. [Last accessed 8 Dec 2022]
   Google Scholar
• Bioprojet Investor Presentation. Available at https://ir.harmonybiosciences.com/static-files/df637c7a-2e0b-4683-82a0-fe8ce20affc2. [Last accessed 8 Dec 2022]
   Google Scholar
• The voice of the patient. Available at https://www.fda.gov/media/88736/download. [Last accessed 8 Dec 2022]
   Google Scholar
• Thakrar C, Patel K, D’Ancona G, et al. Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice. J Sleep Res. 2018;27:1–10.
   Web of Science ®Google Scholar
• Jazz pharmaceuticals (JAZZ) sleep 2017 investor update slide-show. Available at https://seekingalpha.com/article/4079644-jazz-pharmaceuticals-jazz-sleep-2017-investor-update-slideshow [Last accessed 10 Dec 2022]
   Google Scholar
• Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45(6):zsab200. PMID: 34358324; PMCID: PMC9189976. 10.1093/sleep/zsab200
   PubMed Web of Science ®Google Scholar
• Roth T, Dauvilliers Y, Thorpy MJ, et al. Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase III REST-ON trial. CNS Drugs. 2022;36:377–387.
   PubMed Web of Science ®Google Scholar
• Jazz pharma expands neuroscience pipeline with $7.2B GW acquisition. Available at https://www.genengnews.com/news/jazz-pharma-expands-neuroscience-pipeline-with-7-2b-gw-acquisition/[Last accessed 20 Dec 2022]
   Google Scholar
• Canafax D, Xiang W, Xiang JN. Clinical PK of XW 10172 for once nightly therapy in patients with narcolepsy of sleep disorders in neurodegenerative disease. Abs Sleep. 2021;44:A197.
   Web of Science ®Google Scholar
• Jazz acquires DSP-0187. Available at https://www.neurologylive.com/view/jazz-acquires-narcolepsy-hopeful-dsp-0187-jzp441-agreement-sumitomo-pharma [Last accessed 4 Dec 2022]
   Google Scholar
• Tanaka S‐I, Evans R, Alexander R, et al. Selective orexin 2 receptor agonist TAK-925 to treat narcolepsy: results of a randomized, double-blind, placebo-controlled, multiple-ascending-dose, phase 1 study in patients with narcolepsy type 1. J Sleep Res. 2020;29(SUPPL 1). 28 Feb 2021. | added to CENTRAL: | 2021 Issue 02: https://doi.org.laneproxy.stanford.edu/10.1111/jsr.13181
   Google Scholar
• Takeda update on TAK-994. Available at https://www.takeda.com/newsroom/newsreleases/2021/takeda-provides-update-on-tak-994-clinical-program/[Last accessed 9 Dec 2022]
   Google Scholar
• Effect of intranasal administration of orexin a on il-6 system, sleep-wake regulation and neurocognition. Available at https://clinicaltrials.gov/ct2/show/NCT00484757?term=NCT+00484757&cond=Narcolepsy&draw=2&rank=1 [Last accessed 12 Dec 2022]
   Google Scholar
• O’Gorman C, Jones A, Thorpy MJ. Efficacy and safety of AXS-12 in the treatment of narcolepsy: results from a phase 2, double-blind, placebo-controlled, crossover trial. Sleep. 2020 Apr;43(Supplement_1):A281. DOI:10.1093/sleep/zsaa056.735.
   Google Scholar
• Hopkins SC, Dedic N, Koblan KS. Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans. Transl Psychiatry. 2021;11:228.
   PubMed Web of Science ®Google Scholar
• Study on the effects of multiple doses of an investigational drug taken by mouth in people with narcolepsy/cataplexy. Available at https://clinicaltrials.gov/ct2/results?term=NCT+05015673&Search=Search [Last accessed 15 Dec 2022]
   Google Scholar
• Positive results for phase 2A trial of mazindol ER. Available at https://www.biospace.com/article/releases/nls-pharmaceutics-announces-positive-top-line-results-from-its-phase-2a-clinical-trial-of-once-daily-quilience-r-mazindol-er-for-the-treatment-of-excessive-daytime-sleepiness-and-cataplexy-in-patients-with-narcolepsy/. [Last accessed on 11 Dec 2022]
   Google Scholar
• Inoue Y, Uchiyama M, Umeuchi H, et al. Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials. BMC Psychiatry. 2022 Feb 22;22(1):141.
   PubMed Web of Science ®Google Scholar
• Nirogi R, Mudigonda K, Bhyrapuneni G, et al. Safety, tolerability, and pharmacokinetics of SUVN-G3031, a novel histamine-3 receptor inverse agonist for the treatment of narcolepsy, in healthy human subjects following single and multiple oral doses. Clin Drug Investig. 2020 Jul;40(7):603–615.
   PubMed Web of Science ®Google Scholar
• A safety and effectiveness study of a single dose of JNJ-17216498 in patients with narcolepsy. Available at https://clinicaltrials.gov/ct2/show/NCT00424931?term=JNJ+17216498&cond=narcolepsy&draw=2&rank=1 [Last accessed 24 Dec 2022]
   Google Scholar
• A study of safety and efficacy of BTD-001 in treatment of patients with idiopathic hypersomnia (ih) or narcolepsy type 2. Available at https://clinicaltrials.gov/ct2/show/NCT02512588?term=BTD+001&cond=narcolepsy&draw=2&rank=1 [Last accessed 25 Dec 2022]
   Google Scholar
• Theranos announces preliminary results of phase 11 trial of THN102 on narcolepsy patients [press release]. Available at https://www.theranexus.com/images/pdf/Theranexus_PR_result_narcolepsy_20199227_VDEF.pdf [Last accessed 11 Dec 2022]
   Google Scholar
• Trotti LM, Saini P, Bliwise DL, et al. Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: a randomized, crossover trial. Ann Neurol. 2015 Sep;78(3):454–465.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information. Available at https://www.xywavhcp.com/pdf/xywav.en.USPI.pdf [Last accessed 4 Dec 2022]
   Google Scholar
• International Study Group X, Xyrem International Study Group.Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005 Sep;6(5):415–421. PMID: 16099718. DOI:10.1016/j.sleep.2005.03.010
   PubMed Web of Science ®Google Scholar
• Steffen AD, Lai C, Weaver TE. Criteria for gauging response to sodium oxybate for narcolepsy. J Sleep Res. 2018 Aug;27(4):e12628. Epub 2017 Dec 5. PMID: 29205601. DOI:10.1111/jsr.12628
   PubMed Web of Science ®Google Scholar
• Chen C, Jenkins J, Zomorodi K, et al. Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies. Clin Transl Sci. 2021;14:2278–2287. DOI:10.1111/cts.13087
   PubMed Web of Science ®Google Scholar
• Junnarkar G, Allphin C, Profant J, et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov. 2022;17:109–119.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3):zsaa206. DOI:10.1093/sleep/zsaa206
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Sonka K, Bogan RK, et al. Changes in cataplexy frequency in a clinical trial of lower-sodium oxybate with taper and discontinuation of other anticataplectic medications. CNS Drugs. 2022;202(6):633–647. DOI:10.1007/s40263-022-00926-0
   Google Scholar
• Lecendreux M, Plazzi G, Dauvilliers Y, et al. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients. J Clin Sleep Med. 2022 Sep 1. 18(9);2217–2227. DOI:10.5664/jcsm.10090. PMID: 35689598; PMCID: PMC9435339.
   PubMed Web of Science ®Google Scholar
• Plazzi G, Ruoff C, Lecendreux M, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Lancet Child Adolesc Health. 2018 Jul;2(7):483–494. Epub 2018 May 21. PMID: 30169321. DOI:10.1016/S2352-4642(18)30133-0
   PubMedGoogle Scholar
• Husain A, Leary E, Fuller D, et al. Dosing and reasons for transitioning from sodium oxybate to lower sodium oxybate in people with narcolepsy: data from the real world TENOR study. Sleep. 2022;45(Supp 1):A174. DOI:10.1093/sleep/zsac079.385
   Google Scholar
• Leary E, Zee P, Fuller D, et al. Efficacy and safety in people with narcolepsy transitioning from sodium oxybate to lower sodium oxybate: data from the real world TENOR study. Sleep. 2022;45(Supp 1):A176. DOI:10.1093/sleep/zsac079.391
   Google Scholar
• Leary E, Kirby T, Skowronski R, et al. Effectiveness and treatment optimization among participants with narcolepsy switching from sodium oxybate to lower sodium oxybate; interim data from the SEGUE study. Sleep. 2022;45(Supp 1):A177. DOI:10.1093/sleep/zsac079.392
   Google Scholar
• Study Group USXM, U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5:119–123.
   PubMed Web of Science ®Google Scholar
• Ristanovic RK, Liang H, Hornfeldt CS, et al. Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy. Sleep Med. 2009;10:416–421.
   PubMed Web of Science ®Google Scholar
• Bogan R, Foldvary-Schaefer N, Skowronski R, et al. Timing and duration of adverse events in a clinical trial of lower-sodium oxybate in participants with narcolepsy with cataplexy. Abs Sleep. 2022;45(Supp1):A192. DOI:10.1093/sleep/zsac079.383
   Google Scholar
• Foldvary-Schaefer N, Skowronski R, Hickey L, et al. Weight changes during treatment with lower sodium oxybate in a phase 3 clinical study in patients with narcolepsy. Abs Sleep. 2022;45(Supp 1):A176. DOI:10.1093/sleep/zsac079.390
   Google Scholar
• REMS document for Xywav with last update 07/2020. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212690Orig1s000REMS.pdf [Last accessed on 7 Dec 2022].
   Google Scholar
• Strunc MJ, Black J, Lillaney P, et al. The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) program in the USA: results from 2016 to 2017. Drugs Real World Outcomes. 2021;8:15–28.
   PubMedGoogle Scholar
• Iranzo A, Serralheiro P, Schuller JC, et al. Evaluation of the effectiveness of the risk minimization measures of sodium oxybate in the European Union. Drugs Real World Outcomes. 2020 Dec;7(4):307–315. DOI:10.1007/s40801-020-00212-9. PMID: 32989679; PMCID: PMC7581670.
   PubMedGoogle Scholar
• Avidan AY, Kushida CA. The sodium in sodium oxybate: is there cause for concern? Sleep Med. 2020 Nov: 75;497–501. DOI:10.1016/j.sleep.2020.09.017. Epub 2020 Sep 21. PMID: 33022487.
   PubMed Web of Science ®Google Scholar
• Drakatos P, Lykouras D, D’Ancona G, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017 Jul;35:80–84. DOI: 10.1016/j.sleep.2017.03.028. Epub 2017 May 6. PMID: 28619187; PMCID: PMC5727622.
   PubMed Web of Science ®Google Scholar
• Mayer G, Plazzi G, Iranzo Á, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep. 2018 Sep 1:41(9). DOI:10.1093/sleep/zsy128. PMID: 29986085.
   Web of Science ®Google Scholar
• Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009 Aug 15:5(4);365–371. DOI: 10.5664/jcsm.27549. Erratum in Erratum in Erratum in.
   PubMed Web of Science ®Google Scholar
• Alomar M, Tawfiq AM, Hassan N, et al. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020 Aug 10;11:2042098620938595. DOI:10.1177/2042098620938595. PMID: 32843958; PMCID: PMC7418468.
   Web of Science ®Google Scholar
• Jennum PJ, Plazzi G, Silvani A, et al. Cardiovascular disorders in narcolepsy: review of associations and determinants. Sleep Med Rev. 2021 AugJan;58:101440. DOI:10.1016/j.smrv.2021.101440 Epub PMID: 33582582 [2021 23].
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013 Jun;14(6):488–492. Epub 2013 May 3. PMID: 23643648. DOI:10.1016/j.sleep.2013.03.002
   PubMed Web of Science ®Google Scholar
• Cohen A, Mandrekar J, St Louis EK, et al. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018 Mar;43:14–18.
   PubMed Web of Science ®Google Scholar
• Cook NR, He FJ, MacGregor GA, et al. Sodium and health-concordance and controversy. BMJ. 2020 Jun 26;369:m2440. Erratum in: BMJ. 2020 Jun 29;369:m2608. He, J [corrected to He, Feng J]. PMID: 32591335; PMCID: PMC7318881. DOI:10.1136/bmj.m2440
   PubMedGoogle Scholar
• Cappuccio FP, Campbell NRC, He FJ, et al. Sodium and health: old myths and a controversy based on denial. Curr Nutr Rep. 2022 Jun;11(2):172–184. DOI:10.1007/s13668-021-00383-z. Epub 2022 Feb 14. PMID: 35165869; PMCID: PMC9174123.
   PubMedGoogle Scholar
• Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013 Apr 3;346:f1326. DOI:10.1136/bmj.f1326. PMID: 23558163; PMCID: PMC4816261
   PubMed Web of Science ®Google Scholar
• Gardener H, Rundek T, Wright CB, et al. Dietary sodium and risk of stroke in the Northern Manhattan study. Stroke. 2012 May;43(5):1200–1205. Epub 2012 Apr 12. PMID: 22499576; PMCID: PMC3347890. DOI:10.1161/STROKEAHA.111.641043
   PubMed Web of Science ®Google Scholar
• Malta D, Petersen KS, Johnson C, et al. High sodium intake increases blood pressure and risk of kidney disease. From the Science of Salt: a regularly updated systematic review of salt and health outcomes (August 2016 to March 2017). J Clin Hypertens (Greenwich). 2018 Dec;20(12):1654–1665. DOI:10.1111/jch.13408. Epub 2018 Nov 7. PMID: 30402970; PMCID: PMC8030856.
   PubMed Web of Science ®Google Scholar
• George J, Majeed W, Mackenzie IS, et al. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ. 2013 Nov 26;347:f6954. PMID: 24284017; PMCID: PMC3898660. DOI:10.1136/bmj.f6954
   PubMed Web of Science ®Google Scholar
• Wang YJ, Yeh TL, Shih MC, et al. Dietary sodium intake and risk of cardiovascular disease: a systematic review and dose-response meta-analysis. Nutrients. 2020 Sep 25;12(10):2934. PMID: 32992705; PMCID: PMC7601012. DOI:10.3390/nu12102934
   PubMed Web of Science ®Google Scholar
• Poggio R, Gutierrez L, Matta MG, et al. Daily sodium consumption and CVD mortality in the general population: systematic review and meta-analysis of prospective studies. Public Health Nutr. 2015;18:695–704.
   PubMed Web of Science ®Google Scholar
• Strazzullo P, D’Elia L, Kandala N, et al. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.
   PubMed Web of Science ®Google Scholar
• Milajerdi A, Djafarian K, Shab-Bidar S. Dose–response association of dietary sodium intake with all-cause and cardiovascular mortality: a systematic review and meta-analysis of prospective studies. Public Health Nutr. 2019;22:295–306.
   PubMed Web of Science ®Google Scholar
• Inocente CO, Lavault S, Lecendreux M, et al. Impact of obesity in children with narcolepsy. CNS Neurosci Ther. 2013 Jul;19(7):521–528. DOI:10.1111/cns.12105. Epub 2013 Apr 10. PMID: 23574649; PMCID: PMC6493658.
   PubMed Web of Science ®Google Scholar
• Ponziani V, Gennari M, Pizza F, et al. Growing up with type 1 narcolepsy: its anthropometric and endocrine features. J Clin Sleep Med. 2016;12(12):1649–1657. DOI:10.5664/jcsm.6352
   PubMed Web of Science ®Google Scholar
• Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018 Dec 1;41(12):zsy185. DOI:10.1093/sleep/zsy185 PMID: 30239930; PMCID: PMC6289237.
   PubMed Web of Science ®Google Scholar
• Chien PY, Kuo CY, Lin MH, et al. Pharmacological interventions for excessive daytime sleepiness in adults with narcolepsy: a systematic review and network meta-analysis. J Clin Med. 2022 Oct 26;11(21):6302. PMID: 36362535; PMCID: PMC9654433. DOI:10.3390/jcm11216302
   PubMed Web of Science ®Google Scholar
• Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017 Mar 3;9:39–57. DOI:10.2147/NSS.S103467. PMID: 28424564; PMCID: PMC5344488
   PubMed Web of Science ®Google Scholar